Immvira Bioscience's Hong Kong IPO Prospectus Expires on July 14, Six Months After Submission

CICC-2.13%
According to Zhitong Caijing, Immvira Bioscience Inc.'s Hong Kong IPO prospectus will expire on July 14, 2026, six months after it was submitted on January 14, 2026. Citi and China International Capital Corporation (CICC) are the joint sponsors for the offering. Immvira is a clinical-need-oriented biotech company focused on oncolytic immunotherapy and engineered exosome therapies.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments